Mode
Text Size
Log in / Sign up
Phase 3 N=795 Randomized Quadruple-blind Treatment

A Study for Patients With Head and Neck Cancer

Head and Neck Neoplasms

Enrolled (actual)
795
Serious AEs
40.8%
Results posted
Apr 2011
Primary outcome: Primary: Overall Survival (OS) — 7.33; 6.28 Months — p=0.082

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
pemetrexed (Drug); cisplatin (Drug); placebo (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Eli Lilly and Company
Primary completion
Mar 2010

Outcome Measures

OutcomeResultp-value
PRIMARY
Overall Survival (OS)
7.33; 6.28 0.082
SECONDARY
Progression-free Survival (PFS)
3.61; 2.79 0.166
SECONDARY
Percent of Participants With a Tumor Response (Response Rate)
12.1; 8.1 0.061
SECONDARY
Duration of Response (DoR)
5.29; 4.37 0.811
SECONDARY
Time to Treatment Worsening in Functional Assessment of Cancer Therapy - Head and Neck Cancer (FACT-H&N) Total Score
3.29; 2.89 0.20
SECONDARY
Correlation Between Biomarkers and Treatment Effect

Summary

This study will compare the effects of pemetrexed plus cisplatin versus cisplatin alone in head and neck cancer patients.

Eligibility Criteria

Inclusion Criteria

  • You must have head and neck cancer that has returned and cannot be treated with surgery or other types of treatment. OR You must have head and neck cancer that was just found and has spread to other parts of your body.
  • You must have a performance status of 0,1 or 2. This means that you must at least be able to get around, be able to take care of yourself and must be up and about most of the day.
  • Your test results must show that your liver, kidneys and blood cells are working normally.
  • You must understand and sign the form that gives your agreement to willingly be part of the study.
  • You must be at least 18 years of age.

Exclusion Criteria

  • You cannot have previously been given other treatment for cancer that has spread to other parts of your body.
  • You cannot have a serious sickness that might keep you from finishing the study (for example a bad infection).
  • You cannot have any extra fluid in your chest or bowel area unless your doctor tells you it can be drained before you join the study.
  • You cannot have any cancer called nasopharyngeal cancer, paranasal sinus cancer, lip cancer, or salivary gland cancer.
  • If you are taking high dose aspirin or other medicines called non-steroidal anti-inflammatory drugs and cannot stop taking them for at least 5 days, you cannot be in the study. Your doctor or a member of the study team can explain which drugs are non-steroidal anti-inflammatory drugs.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00415194). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search